StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

Analysts at StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK – Get Rating) in a research note issued on Friday. The firm set a “sell” rating on the medical research company’s stock.

Separately, HC Wainwright dropped their price target on Check-Cap from $15.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, April 5th.

Check-Cap Price Performance

Check-Cap stock opened at $1.47 on Friday. The stock has a market capitalization of $7.09 million and a PE ratio of -0.66. Check-Cap has a 12 month low of $1.22 and a 12 month high of $9.20. The business has a 50 day simple moving average of $1.50 and a 200-day simple moving average of $2.73.

Check-Cap (NASDAQ:CHEK – Get Rating) last posted its quarterly earnings data on Friday, March 31st. The medical research company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.04. On average, equities research analysts anticipate that Check-Cap will post -1.8 EPS for the current fiscal year.

Institutional Trading of Check-Cap

Several large investors have recently made changes to their positions in CHEK. Sabby Management LLC purchased a new stake in Check-Cap in the 1st quarter valued at $91,000. Virtu Financial LLC grew its holdings in Check-Cap by 363.4% in the 2nd quarter. Virtu Financial LLC now owns 224,696 shares of the medical research company’s stock valued at $69,000 after buying an additional 176,207 shares in the last quarter. Susquehanna International Group LLP purchased a new stake in Check-Cap in the 1st quarter valued at $57,000. Finally, Citadel Advisors LLC grew its holdings in Check-Cap by 51.2% in the 3rd quarter. Citadel Advisors LLC now owns 141,319 shares of the medical research company’s stock valued at $41,000 after buying an additional 47,868 shares in the last quarter. 17.59% of the stock is currently owned by hedge funds and other institutional investors.

Check-Cap Company Profile

(Get Rating)

Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule system for colorectal cancer screening. Its patented technology, C-Scan, is a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer.